Safety and Efficacy of Percutaneous Cryoablation for Small Hepatocellular Carcinomas Adjacent to the Heart

Joon Ho Kwon, Jong Yun Won, Kichang Han, Seungchul Han, Doyoung Kim, Heejoon Kim, Gyoung Min Kim, Man Deuk Kim, Do Yun Lee

Research output: Contribution to journalArticle

Abstract

Purpose: This study evaluated the safety and efficacy of percutaneous cryoablation for treatment of the left subdiaphragmatic small hepatocellular carcinomas (HCCs) adjacent to the heart. Materials and Methods: Between September 2013 and March 2018, 189 consecutive patients underwent cryoablation for small HCCs (≤3 cm); 70 patients (mean: 61.3 ± 10.6 years of age; range: 40–82 years) with left hepatic tumors (22 juxtacardiac and 48 nonjuxtacardiac tumors) were retrospectively analyzed. Patients were divided into juxtacardiac and nonjuxtacardiac tumor groups (tumor margins: ≤10 mm and >10 mm, respectively, from the heart border). The rates of technical success, complete ablation, complications, and local tumor recurrence (LTR) were evaluated. Results: No significant intergroup differences were observed in the mean diameter of the tumor (17.9 ± 5.5 mm vs. 17.5 mm ± 5.2, respectively; P = 0.781) and of the ablation zone (41.3 ± 4.2 mm vs. 43.5 ± 5.8 mm, respectively; P = 0.115). Technical success was achieved in all patients. No procedure-related major complications occurred in either group. The median follow-up period was 15 months (range: 3.1–49.6 months). No statistically significant intergroup differences were observed in the rates of complete ablation (90.9% vs. 93.8%, respectively; P = 0.646) and LTR (20% vs. 15.6%, respectively; P = 0.725). Conclusions: Cryoablation is a safe treatment modality for patients with juxtacardiac small HCCs, without an increased risk of cardiac complications compared to treatment of HCCs that are nonjuxtacardiac, and with comparable efficacy.

Original languageEnglish
Pages (from-to)1223-1228
Number of pages6
JournalJournal of Vascular and Interventional Radiology
Volume30
Issue number8
DOIs
Publication statusPublished - 2019 Aug

Fingerprint

Cryosurgery
Hepatocellular Carcinoma
Safety
Neoplasms
Recurrence
Therapeutics
Liver

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Kwon, Joon Ho ; Won, Jong Yun ; Han, Kichang ; Han, Seungchul ; Kim, Doyoung ; Kim, Heejoon ; Kim, Gyoung Min ; Kim, Man Deuk ; Lee, Do Yun. / Safety and Efficacy of Percutaneous Cryoablation for Small Hepatocellular Carcinomas Adjacent to the Heart. In: Journal of Vascular and Interventional Radiology. 2019 ; Vol. 30, No. 8. pp. 1223-1228.
@article{dcf72a29c176478987a7cee63ba4c653,
title = "Safety and Efficacy of Percutaneous Cryoablation for Small Hepatocellular Carcinomas Adjacent to the Heart",
abstract = "Purpose: This study evaluated the safety and efficacy of percutaneous cryoablation for treatment of the left subdiaphragmatic small hepatocellular carcinomas (HCCs) adjacent to the heart. Materials and Methods: Between September 2013 and March 2018, 189 consecutive patients underwent cryoablation for small HCCs (≤3 cm); 70 patients (mean: 61.3 ± 10.6 years of age; range: 40–82 years) with left hepatic tumors (22 juxtacardiac and 48 nonjuxtacardiac tumors) were retrospectively analyzed. Patients were divided into juxtacardiac and nonjuxtacardiac tumor groups (tumor margins: ≤10 mm and >10 mm, respectively, from the heart border). The rates of technical success, complete ablation, complications, and local tumor recurrence (LTR) were evaluated. Results: No significant intergroup differences were observed in the mean diameter of the tumor (17.9 ± 5.5 mm vs. 17.5 mm ± 5.2, respectively; P = 0.781) and of the ablation zone (41.3 ± 4.2 mm vs. 43.5 ± 5.8 mm, respectively; P = 0.115). Technical success was achieved in all patients. No procedure-related major complications occurred in either group. The median follow-up period was 15 months (range: 3.1–49.6 months). No statistically significant intergroup differences were observed in the rates of complete ablation (90.9{\%} vs. 93.8{\%}, respectively; P = 0.646) and LTR (20{\%} vs. 15.6{\%}, respectively; P = 0.725). Conclusions: Cryoablation is a safe treatment modality for patients with juxtacardiac small HCCs, without an increased risk of cardiac complications compared to treatment of HCCs that are nonjuxtacardiac, and with comparable efficacy.",
author = "Kwon, {Joon Ho} and Won, {Jong Yun} and Kichang Han and Seungchul Han and Doyoung Kim and Heejoon Kim and Kim, {Gyoung Min} and Kim, {Man Deuk} and Lee, {Do Yun}",
year = "2019",
month = "8",
doi = "10.1016/j.jvir.2018.12.030",
language = "English",
volume = "30",
pages = "1223--1228",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "8",

}

Safety and Efficacy of Percutaneous Cryoablation for Small Hepatocellular Carcinomas Adjacent to the Heart. / Kwon, Joon Ho; Won, Jong Yun; Han, Kichang; Han, Seungchul; Kim, Doyoung; Kim, Heejoon; Kim, Gyoung Min; Kim, Man Deuk; Lee, Do Yun.

In: Journal of Vascular and Interventional Radiology, Vol. 30, No. 8, 08.2019, p. 1223-1228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and Efficacy of Percutaneous Cryoablation for Small Hepatocellular Carcinomas Adjacent to the Heart

AU - Kwon, Joon Ho

AU - Won, Jong Yun

AU - Han, Kichang

AU - Han, Seungchul

AU - Kim, Doyoung

AU - Kim, Heejoon

AU - Kim, Gyoung Min

AU - Kim, Man Deuk

AU - Lee, Do Yun

PY - 2019/8

Y1 - 2019/8

N2 - Purpose: This study evaluated the safety and efficacy of percutaneous cryoablation for treatment of the left subdiaphragmatic small hepatocellular carcinomas (HCCs) adjacent to the heart. Materials and Methods: Between September 2013 and March 2018, 189 consecutive patients underwent cryoablation for small HCCs (≤3 cm); 70 patients (mean: 61.3 ± 10.6 years of age; range: 40–82 years) with left hepatic tumors (22 juxtacardiac and 48 nonjuxtacardiac tumors) were retrospectively analyzed. Patients were divided into juxtacardiac and nonjuxtacardiac tumor groups (tumor margins: ≤10 mm and >10 mm, respectively, from the heart border). The rates of technical success, complete ablation, complications, and local tumor recurrence (LTR) were evaluated. Results: No significant intergroup differences were observed in the mean diameter of the tumor (17.9 ± 5.5 mm vs. 17.5 mm ± 5.2, respectively; P = 0.781) and of the ablation zone (41.3 ± 4.2 mm vs. 43.5 ± 5.8 mm, respectively; P = 0.115). Technical success was achieved in all patients. No procedure-related major complications occurred in either group. The median follow-up period was 15 months (range: 3.1–49.6 months). No statistically significant intergroup differences were observed in the rates of complete ablation (90.9% vs. 93.8%, respectively; P = 0.646) and LTR (20% vs. 15.6%, respectively; P = 0.725). Conclusions: Cryoablation is a safe treatment modality for patients with juxtacardiac small HCCs, without an increased risk of cardiac complications compared to treatment of HCCs that are nonjuxtacardiac, and with comparable efficacy.

AB - Purpose: This study evaluated the safety and efficacy of percutaneous cryoablation for treatment of the left subdiaphragmatic small hepatocellular carcinomas (HCCs) adjacent to the heart. Materials and Methods: Between September 2013 and March 2018, 189 consecutive patients underwent cryoablation for small HCCs (≤3 cm); 70 patients (mean: 61.3 ± 10.6 years of age; range: 40–82 years) with left hepatic tumors (22 juxtacardiac and 48 nonjuxtacardiac tumors) were retrospectively analyzed. Patients were divided into juxtacardiac and nonjuxtacardiac tumor groups (tumor margins: ≤10 mm and >10 mm, respectively, from the heart border). The rates of technical success, complete ablation, complications, and local tumor recurrence (LTR) were evaluated. Results: No significant intergroup differences were observed in the mean diameter of the tumor (17.9 ± 5.5 mm vs. 17.5 mm ± 5.2, respectively; P = 0.781) and of the ablation zone (41.3 ± 4.2 mm vs. 43.5 ± 5.8 mm, respectively; P = 0.115). Technical success was achieved in all patients. No procedure-related major complications occurred in either group. The median follow-up period was 15 months (range: 3.1–49.6 months). No statistically significant intergroup differences were observed in the rates of complete ablation (90.9% vs. 93.8%, respectively; P = 0.646) and LTR (20% vs. 15.6%, respectively; P = 0.725). Conclusions: Cryoablation is a safe treatment modality for patients with juxtacardiac small HCCs, without an increased risk of cardiac complications compared to treatment of HCCs that are nonjuxtacardiac, and with comparable efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85063917188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063917188&partnerID=8YFLogxK

U2 - 10.1016/j.jvir.2018.12.030

DO - 10.1016/j.jvir.2018.12.030

M3 - Article

C2 - 30956074

AN - SCOPUS:85063917188

VL - 30

SP - 1223

EP - 1228

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 8

ER -